Physician profile
Donna E Colligan
NPI 1730100165
$5,550.75
in general payments reported to CMS, 2019-2025
41 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $438 · 2023: $988 · 2024: $1,661 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,149 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $747.01 | 2021-2025 | |
| Amgen INC. | $574.95 | 2021-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $434.25 | 2021-2025 | Airsupra, Breztri, Wainua |
| Novo Nordisk INC | $400.40 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $372.37 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $278.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $243.13 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $202.35 | 2021-2022 | |
| Pfizer INC. | $197.69 | 2021-2025 | |
| Abbott Laboratories | $180.48 | 2025 | Aveir |
| Cleerly, INC. | $170.89 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Esperion Therapeutics, INC. | $166.75 | 2021-2024 | Nexletol |
| Heartflow, INC. | $144.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $120.28 | 2021-2024 | |
| Genzyme Corporation | $119.81 | 2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $118.43 | 2023 | Tremfya |
| Amarin Pharma, INC. | $108.87 | 2021-2023 | |
| Glaxosmithkline, LLC. | $91.55 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Almatica Pharma LLC | $73.09 | 2022-2023 | Loreev Xr |
| Inspire Medical Systems, INC. | $72.79 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $69.71 | 2022-2025 | Watchman Flx, Watchman Access System |
| Biogen, INC. | $61.92 | 2021 | |
| Sumitomo Pharma America, INC. | $60.00 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $57.28 | 2023-2025 | Rexulti |
| Eisai INC. | $56.67 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $45.36 | 2021-2023 | Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.81 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $43.54 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $35.42 | 2021-2025 | Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $28.92 | 2024 | Voquezna |
| Optinose US, INC. | $27.72 | 2025 | |
| Ani Pharmaceuticals, INC. | $26.87 | 2024 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $26.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.06 | 2025 | Vpriv |
| Xeris Pharmaceuticals, INC. | $21.44 | 2022 | |
| Cvrx, INC. | $21.39 | 2025 | Barostim Neo System |
| Sun Pharmaceutical Industries INC. | $19.32 | 2021 | |
| Mylan Specialty L.P. | $18.21 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2024 | Jardiance |
| Radius Health, INC. | $13.81 | 2021 | |
| Medicure Pharma INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Colligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.